Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Status Epilepticus | 24 | 2025 | 158 | 5.450 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 4 | 2025 | 55 | 2.350 |
Why?
|
| Electrocardiography | 4 | 2024 | 1014 | 1.990 |
Why?
|
| Seizures, Febrile | 4 | 2025 | 31 | 1.870 |
Why?
|
| Drug Resistant Epilepsy | 13 | 2025 | 235 | 1.830 |
Why?
|
| Epilepsy | 7 | 2024 | 889 | 1.780 |
Why?
|
| Dexamethasone | 4 | 2025 | 274 | 1.410 |
Why?
|
| Critical Care | 3 | 2024 | 686 | 1.250 |
Why?
|
| Electroencephalography | 8 | 2023 | 908 | 1.190 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 3 | 2017 | 26 | 1.120 |
Why?
|
| Anticonvulsants | 10 | 2025 | 390 | 1.010 |
Why?
|
| Brain Injuries | 9 | 2023 | 716 | 1.000 |
Why?
|
| Benzodiazepines | 7 | 2025 | 109 | 0.970 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2017 | 61 | 0.850 |
Why?
|
| Epileptic Syndromes | 2 | 2021 | 33 | 0.830 |
Why?
|
| Neurophysiological Monitoring | 1 | 2023 | 37 | 0.810 |
Why?
|
| Brain Diseases | 2 | 2023 | 305 | 0.800 |
Why?
|
| Child | 35 | 2025 | 25786 | 0.770 |
Why?
|
| Nervous System Diseases | 2 | 2024 | 408 | 0.720 |
Why?
|
| Heart Arrest | 2 | 2024 | 374 | 0.680 |
Why?
|
| Cytokines | 2 | 2025 | 1359 | 0.660 |
Why?
|
| Neurology | 1 | 2022 | 117 | 0.660 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 553 | 0.660 |
Why?
|
| White Matter | 1 | 2022 | 214 | 0.650 |
Why?
|
| Immunotherapy | 1 | 2025 | 745 | 0.620 |
Why?
|
| Time-to-Treatment | 4 | 2025 | 211 | 0.610 |
Why?
|
| Child, Preschool | 25 | 2025 | 14749 | 0.610 |
Why?
|
| Blood Pressure | 1 | 2024 | 1400 | 0.580 |
Why?
|
| Mitochondria | 3 | 2017 | 747 | 0.580 |
Why?
|
| Hippocampus | 5 | 2022 | 816 | 0.560 |
Why?
|
| Encephalitis | 3 | 2024 | 118 | 0.540 |
Why?
|
| HSP70 Heat-Shock Proteins | 3 | 2005 | 74 | 0.450 |
Why?
|
| Mitochondrial Diseases | 2 | 2007 | 147 | 0.450 |
Why?
|
| Hospitals, Pediatric | 5 | 2022 | 777 | 0.440 |
Why?
|
| Infant | 19 | 2025 | 13061 | 0.430 |
Why?
|
| Retrospective Studies | 17 | 2025 | 17416 | 0.420 |
Why?
|
| Neurons | 4 | 2017 | 1998 | 0.420 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 489 | 0.420 |
Why?
|
| Humans | 43 | 2025 | 132089 | 0.410 |
Why?
|
| Heart Rate | 1 | 2016 | 588 | 0.410 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2018 | 1222 | 0.400 |
Why?
|
| Injections, Spinal | 4 | 2025 | 135 | 0.390 |
Why?
|
| Kainic Acid | 4 | 2020 | 24 | 0.360 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2022 | 91 | 0.340 |
Why?
|
| Rats | 9 | 2022 | 3609 | 0.330 |
Why?
|
| Male | 31 | 2025 | 64967 | 0.330 |
Why?
|
| Seawater | 1 | 2019 | 14 | 0.320 |
Why?
|
| Bivalvia | 1 | 2019 | 14 | 0.320 |
Why?
|
| Blotting, Western | 5 | 2017 | 1077 | 0.300 |
Why?
|
| Symbiosis | 1 | 2019 | 103 | 0.290 |
Why?
|
| Adolescent | 16 | 2025 | 20560 | 0.290 |
Why?
|
| Seizures | 6 | 2023 | 893 | 0.290 |
Why?
|
| Poly Adenosine Diphosphate Ribose | 1 | 2007 | 5 | 0.280 |
Why?
|
| Disease Progression | 2 | 2024 | 2225 | 0.270 |
Why?
|
| Glutathione | 2 | 2007 | 200 | 0.260 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 260 | 0.240 |
Why?
|
| Chaperonin 60 | 1 | 2006 | 32 | 0.240 |
Why?
|
| Peroxynitrous Acid | 1 | 2005 | 8 | 0.240 |
Why?
|
| Bacteria | 1 | 2019 | 523 | 0.240 |
Why?
|
| Gene Products, tat | 1 | 2005 | 27 | 0.240 |
Why?
|
| Stress, Physiological | 2 | 2006 | 260 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1303 | 0.230 |
Why?
|
| Respiration Disorders | 1 | 2024 | 33 | 0.220 |
Why?
|
| Heart | 2 | 2021 | 690 | 0.220 |
Why?
|
| Transduction, Genetic | 1 | 2005 | 293 | 0.220 |
Why?
|
| Pediatrics | 2 | 2024 | 1213 | 0.210 |
Why?
|
| Glutamic Acid | 1 | 2005 | 209 | 0.210 |
Why?
|
| Autophagy | 1 | 2007 | 426 | 0.210 |
Why?
|
| Clinical Protocols | 1 | 2025 | 239 | 0.210 |
Why?
|
| Female | 24 | 2025 | 70695 | 0.210 |
Why?
|
| Hospitalization | 3 | 2022 | 1900 | 0.200 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 377 | 0.200 |
Why?
|
| Animals | 14 | 2022 | 34798 | 0.190 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2024 | 466 | 0.190 |
Why?
|
| Time Factors | 4 | 2024 | 6448 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 305 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2025 | 6572 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 386 | 0.190 |
Why?
|
| Diet, Ketogenic | 2 | 2021 | 25 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1179 | 0.180 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 540 | 0.180 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2024 | 332 | 0.170 |
Why?
|
| Infectious Encephalitis | 1 | 2020 | 4 | 0.170 |
Why?
|
| Professional Practice Gaps | 1 | 2020 | 15 | 0.170 |
Why?
|
| Circadian Rhythm | 2 | 2020 | 317 | 0.160 |
Why?
|
| Brain | 4 | 2007 | 3176 | 0.160 |
Why?
|
| Photoperiod | 1 | 2019 | 19 | 0.150 |
Why?
|
| Critical Illness | 1 | 2024 | 618 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2021 | 5168 | 0.150 |
Why?
|
| Synapses | 2 | 2022 | 456 | 0.150 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2017 | 41 | 0.150 |
Why?
|
| Receptors, AMPA | 1 | 2018 | 50 | 0.140 |
Why?
|
| Post-Synaptic Density | 1 | 2017 | 11 | 0.140 |
Why?
|
| Emergency Treatment | 1 | 2018 | 86 | 0.140 |
Why?
|
| Synaptotagmin I | 1 | 2017 | 9 | 0.140 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2017 | 9 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 393 | 0.140 |
Why?
|
| Inflammation | 1 | 2025 | 1519 | 0.130 |
Why?
|
| Poly ADP Ribosylation | 1 | 2017 | 1 | 0.130 |
Why?
|
| Dendritic Spines | 1 | 2017 | 58 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1672 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2016 | 13 | 0.130 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2016 | 19 | 0.130 |
Why?
|
| Connexin 43 | 1 | 2016 | 34 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2017 | 361 | 0.130 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4685 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 822 | 0.120 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2016 | 62 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 418 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 142 | 0.120 |
Why?
|
| Antioxidants | 2 | 2009 | 333 | 0.120 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2016 | 144 | 0.120 |
Why?
|
| Young Adult | 7 | 2025 | 9958 | 0.110 |
Why?
|
| Glasgow Coma Scale | 2 | 2006 | 200 | 0.110 |
Why?
|
| Cerebral Cortex | 3 | 2006 | 480 | 0.100 |
Why?
|
| Microscopy, Electron | 2 | 2017 | 337 | 0.100 |
Why?
|
| Child Abuse | 2 | 2005 | 204 | 0.090 |
Why?
|
| Myocardium | 1 | 2016 | 908 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2022 | 3831 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2024 | 456 | 0.080 |
Why?
|
| Fever | 2 | 2025 | 311 | 0.080 |
Why?
|
| Hydrogenase | 1 | 2019 | 1 | 0.080 |
Why?
|
| Mytilidae | 1 | 2019 | 1 | 0.080 |
Why?
|
| Hydrothermal Vents | 1 | 2019 | 1 | 0.080 |
Why?
|
| Biodiversity | 1 | 2019 | 87 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 140 | 0.070 |
Why?
|
| Ecosystem | 1 | 2019 | 107 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2023 | 3416 | 0.070 |
Why?
|
| Cytochromes c | 2 | 2005 | 53 | 0.070 |
Why?
|
| Metagenome | 1 | 2019 | 146 | 0.070 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 90 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2009 | 803 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1694 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2916 | 0.070 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 394 | 0.070 |
Why?
|
| Cell Respiration | 1 | 2007 | 24 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2438 | 0.070 |
Why?
|
| Electron Transport | 1 | 2007 | 57 | 0.070 |
Why?
|
| NAD | 1 | 2007 | 52 | 0.070 |
Why?
|
| Whole-Body Irradiation | 1 | 2007 | 61 | 0.070 |
Why?
|
| Cell Death | 2 | 2005 | 241 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2009 | 170 | 0.070 |
Why?
|
| Nitrogen | 1 | 2007 | 124 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2006 | 876 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 257 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2017 | 3037 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2021 | 1057 | 0.060 |
Why?
|
| Lactate Dehydrogenases | 1 | 2005 | 2 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2005 | 12 | 0.060 |
Why?
|
| Base Sequence | 1 | 2019 | 2899 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2005 | 98 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 100 | 0.060 |
Why?
|
| Animals, Newborn | 2 | 2005 | 1034 | 0.060 |
Why?
|
| Sex Factors | 3 | 2020 | 1355 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 42 | 0.050 |
Why?
|
| Hashimoto Disease | 1 | 2024 | 29 | 0.050 |
Why?
|
| Microbiota | 1 | 2019 | 434 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 125 | 0.050 |
Why?
|
| Accidents | 1 | 2004 | 15 | 0.050 |
Why?
|
| Asphyxia | 1 | 2004 | 14 | 0.050 |
Why?
|
| Florida | 1 | 2024 | 80 | 0.050 |
Why?
|
| Glasgow Outcome Scale | 1 | 2004 | 48 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 811 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2016 | 4704 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 107 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 21 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 1799 | 0.050 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 35 | 0.050 |
Why?
|
| Rituximab | 1 | 2024 | 168 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 791 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2023 | 77 | 0.050 |
Why?
|
| Transcriptome | 1 | 2019 | 1123 | 0.050 |
Why?
|
| Phenotype | 2 | 2023 | 4528 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 99 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2003 | 173 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 183 | 0.050 |
Why?
|
| Midazolam | 1 | 2021 | 44 | 0.050 |
Why?
|
| Craniocerebral Trauma | 1 | 2003 | 140 | 0.040 |
Why?
|
| Apoptosis | 2 | 2005 | 1892 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8549 | 0.040 |
Why?
|
| Cannabidiol | 1 | 2021 | 21 | 0.040 |
Why?
|
| Epilepsy, Generalized | 1 | 2021 | 65 | 0.040 |
Why?
|
| Phenobarbital | 1 | 2020 | 32 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2006 | 785 | 0.040 |
Why?
|
| Phenytoin | 1 | 2020 | 59 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2021 | 52 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1174 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 2322 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 1131 | 0.040 |
Why?
|
| Biomarkers | 2 | 2006 | 3407 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2021 | 13034 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 85 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 547 | 0.040 |
Why?
|
| Aged | 3 | 2025 | 21438 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 118 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2003 | 1047 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 435 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2017 | 81 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 18466 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1439 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 749 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 329 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1460 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 663 | 0.030 |
Why?
|
| Middle Aged | 3 | 2025 | 28998 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1229 | 0.030 |
Why?
|
| Prognosis | 1 | 2006 | 5014 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2019 | 523 | 0.030 |
Why?
|
| Adult | 3 | 2025 | 31575 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 677 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 756 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 779 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 2004 | 143 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2020 | 1087 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2017 | 1234 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2017 | 3861 | 0.020 |
Why?
|
| Caspase 1 | 1 | 2005 | 49 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2005 | 138 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 143 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 165 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 263 | 0.010 |
Why?
|
| Y Chromosome | 1 | 2004 | 47 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 356 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2006 | 255 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 139 | 0.010 |
Why?
|
| Memory Disorders | 1 | 2006 | 210 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 142 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 280 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 270 | 0.010 |
Why?
|
| X Chromosome | 1 | 2004 | 340 | 0.010 |
Why?
|
| HSP72 Heat-Shock Proteins | 1 | 2003 | 2 | 0.010 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2003 | 5 | 0.010 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2004 | 83 | 0.010 |
Why?
|
| United States | 1 | 2018 | 11667 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2004 | 282 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 424 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 866 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 422 | 0.010 |
Why?
|
| Proteomics | 1 | 2006 | 596 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1284 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 1473 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 1248 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1960 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 1977 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 2493 | 0.010 |
Why?
|